The only clinical trial (40 patients) (NCT05170555) testing [177Lu]Lu-EB-PSMA-617 treatment in patients with ccRCC was completed in July 2023, but the results have not been published till now. Here, FOLH1 is linked to nonpapillary renal cell carcinoma.